CareDx cell-free DNA (cFDNA) biomarker in combination with AlloMap increases accuracy of identification of rejection in heart transplant recipients

CareDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant...